On August 14, 2026, Dare Bioscience entered into a securities purchase agreement to sell 4,379,581 shares of common stock and pre-funded warrants at $1.37 per share in a registered direct offering. The company raised approximately $6.0 million in gross proceeds before expenses. Concurrently, the firm issued Series A and Series B warrants exercisable for up to 4,379,581 shares each at an exercise price of $1.37 per share. Proceeds will support working capital, general corporate purposes, and its 503B compounding and consumer health strategies. The closing is expected on August 17, 2026. Dare Bioscience operates in the biotechnology industry, focusing on women's health solutions.
